Uridine Triacetate

尿苷三乙酸酯

Report date: 2022/12/07 17:16:11
NMEFirst In Class

Base Information

Drug NameUridine Triacetate
Drug Alias Name三醋尿苷triacetato de uridinauridini triacetasVistogardXuriden +[8] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionATPase inhibitors
TargetsATPase
Therapy Area/IndicationsChemotherapy induced poisoningHereditary orotic aciduriaSolid tumours +[14] 
Global Approved IndicationsHereditary orotic aciduria
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2015/09/04
Country/TerritoryCanadaUnited StatesPuerto Rico +[4] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesWellstat Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesBtg InternationalWellstat Therapeutics Corp
Inactive CompaniesCarlos Iii Health InstituteRepligen CoBrown University +[9] 
Active IndicationsChemotherapy induced poisoningHereditary orotic aciduriaPoisoning
Inactive IndicationsSolid tumoursStress Disorders, Post-TraumaticAnxiety Disorders +[11] 

Other Information

ATC CodeA16AX13
Related LinksWikipediaDrugBankKEGG